Exclusive financial advisor to Toxikon

KPMG Corporate Finance LLC acted as exclusive financial advisor to Toxikon

KPMG Corporate Finance LLC (KPMG CF) acted as exclusive financial advisor to Toxikon on its sale of the business to Labcorp, a leading global life sciences company.

Toxikon is a leading preclinical contract research organization (CRO) providing in vivo, in vitro, and analytical testing services for the pharmaceutical, biotechnology, and medical device industries worldwide, helping those companies gain approval for their products quickly and bring them to market successfully.

Headquartered in Bedford, Massachusetts, Toxikon maintains specialized, state-of-the-art facilities and a robust roster of pharmaceutical, biotech, and medical device clients. Its highly trained staff provides an extensive portfolio of in vivo and in vitro testing and related consulting services to support life sciences companies. The facility in Bedford also has capacity for growth and provides Labcorp Drug Development with an opportunity to expand its traditional toxicology business.

“As a part of the Labcorp family, we will have an opportunity to broaden our impact through access to extensive resources, knowledge, and support,” said Dr. Laxman S. Desai, Toxikon’s founder, president, and CEO. “Together, we can provide better outcomes for our clients and, ultimately, the healthcare providers and patients who depend on our continued success and innovation.”

Labcorp has more than 70,000 employees and serves clients in more than 100 countries. “Adding Toxikon underscores our commitment to nonclinical development and advances our capabilities for both drug development and medical device testing,” said Dr. Paul Kirchgraber, CEO of Labcorp Drug Development. “This acquisition extends Labcorp’s portfolio of full-service drug development and medical device solutions from discovery to market approval.”

KPMG CF acted as exclusive financial advisor to Toxikon. KPMG CF partnered with the KPMG Financial Due Diligence and Tax Advisory practices to provide a comprehensive and integrated solution for the client.

Dr. Laxman S. Desai further commented: “This transaction was a complex endeavor that took many twists and turns along the way. KPMG CF demonstrated tremendous perseverance and was instrumental in helping us to achieve an optimal result. We would like to thank KPMG CF for their unwavering support.”

Financial details of this transaction are confidential.

Global coverage. Industry knowledge. Middle-market focus.

The global Corporate Finance practice of KPMG International’s network of independent member firms was ranked #1 as the top M&A middle-market adviser globally by Refinitiv, based on number of completed transactions, for the past 20 years.

KPMG Corporate Finance LLC

The global Corporate Finance practice of KPMG International’s network of independent member firms was ranked #1 as the top M&A middle-market adviser globally by Refinitiv, based on number of completed transactions, for the past 20 years.

Trust KPMG Corporate Finance LLC with your next transaction.

KPMG Corporate Finance LLC
Jason Moran
‹
›

Jason Moran

Managing Director, KPMG Corporate Finance LLC

+1 415-418-8474


 
 
Corporate finance services, including Financing, Debt Advisory, and Valuation Services, are not performed by all KPMG member firms and are not offered by member firms in certain jurisdictions due to legal or regulatory constraints. The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act upon such information without appropriate professional advice after a thorough examination of the particular situation. 
 
The information contained in this communication may not be representative of the experience of other clients and does not constitute a recommendation, offer, or solicitation to buy, sell or hold any security of any issuer. Past performance does not guarantee future results.
 
©2023 KPMG Corporate Finance LLC, a Delaware limited liability company. Member FINRA/SIPC. KPMG Corporate Finance LLC is a subsidiary of KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. KPMG Corporate Finance LLC is not engaged in the practice of public accountancy. All rights reserved. The KPMG name and logo are registered trademarks or trademarks of KPMG International.